NCT01784640View on ClinicalTrials.gov

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 11, 2018

Study Completion Date

October 11, 2018

Conditions
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

Hsp90 inhibitor AUY922

Given IV

DRUG

pemetrexed disodium

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

collaborator

Novartis

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER